Compass Therapeutics
Home
About
Platform
Pipeline
Join Us
Investors
Contact
Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity
Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity
Post navigation
Previous Post
Previous
CTX-8371, a Novel Bispecific Targeting both PD-1 and PD-L1, is more Potent than Combination anti-PD-1 and PD-L1 Therapy and Provides Enhanced Protection from Tumors in vivo
Next Post
Next
Phase 1a/1b Dose-escalation Study of ABL001 (CTX-009, Bispecific antibody targeting DLL4 and VEGF-A) as a Single Agent in Patients with Advanced Solid Tumors
Home
About
Platform
Pipeline
Join Us
Investors
Contact